These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20154655)

  • 21. An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes.
    Painter NA; Morello CM; Singh RF; McBane SE
    J Am Board Fam Med; 2013; 26(2):203-10. PubMed ID: 23471935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GLP-1: target for a new class of antidiabetic agents?
    Edwards CM
    J R Soc Med; 2004 Jun; 97(6):270-4. PubMed ID: 15173327
    [No Abstract]   [Full Text] [Related]  

  • 23. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.
    Beiroa D; Imbernon M; Gallego R; Senra A; Herranz D; Villarroya F; Serrano M; Fernø J; Salvador J; Escalada J; Dieguez C; Lopez M; Frühbeck G; Nogueiras R
    Diabetes; 2014 Oct; 63(10):3346-58. PubMed ID: 24917578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
    Minze MG; Klein MS; Jernigan MJ; Wise SL; Frugé K
    Pharmacotherapy; 2013 Jun; 33(6):627-38. PubMed ID: 23553357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Medication of the month... Exenatide (Byetta) incretinomimetic in the treatment of type 2 diabetes after failure and as add-on therapy to oral agents].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2008 Mar; 63(3):158-65. PubMed ID: 18561773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exenatide: a novel approach for treatment of type 2 diabetes.
    Mikhail N
    South Med J; 2006 Nov; 99(11):1271-9. PubMed ID: 17195423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery.
    Iglesias P; Civantos S; Vega B; Pavón I; Guijarro G; Monereo S
    Obes Surg; 2015 Mar; 25(3):575-8. PubMed ID: 25589020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
    Gallwitz B
    Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exenatide: a novel incretin mimetic agent for treating type 2 diabetes mellitus.
    Lam S; See S
    Cardiol Rev; 2006; 14(4):205-11. PubMed ID: 16788334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
    Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
    Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice.
    Gumuslu E; Cine N; Ertan M; Mutlu O; Komsuoglu Celikyurt I; Ulak G
    Fundam Clin Pharmacol; 2018 Apr; 32(2):174-180. PubMed ID: 29091313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
    Consoli A; Di Biagio R
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):5-9. PubMed ID: 22158421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of the haemodynamic effects of exenatide in healthy male subjects.
    Mendis B; Simpson E; MacDonald I; Mansell P
    Br J Clin Pharmacol; 2012 Sep; 74(3):437-44. PubMed ID: 22320349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [GLP-1-based treatment of type 2 diabetes mellitus].
    Knop FK; Vilsbøll T
    Ugeskr Laeger; 2007 May; 169(22):2095-9. PubMed ID: 17553390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
    Reuter H; Erdmann E
    Dtsch Med Wochenschr; 2007 Mar; 132(11):571-4. PubMed ID: 17342635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages.
    Bułdak Ł; Łabuzek K; Bułdak RJ; Machnik G; Bołdys A; Okopień B
    Naunyn Schmiedebergs Arch Pharmacol; 2015 Sep; 388(9):905-19. PubMed ID: 25980358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The value of incretin based therapies].
    Gallwitz B
    Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
    [No Abstract]   [Full Text] [Related]  

  • 40. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; van Raalte DH
    Eur J Endocrinol; 2017 Jan; 176(1):77-86. PubMed ID: 27777261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.